Brenig Therapeutics
Brenig Therapeutics is a small molecule drug discovery company focused on developing breakthrough treatments for neurodegenerative diseases. Founded in 2021, the company utilizes advanced hybrid AI/ML platforms, biomarker-driven precision development, and strategic partnerships to accelerate the translation of research into therapies. They aim to deliver best-in-class drug candidates from initial design to clinic within three years, supported by Expert Systems, Inc. Brenig has secured $65 million in Series A financing and is advancing its pre-clinical Parkinson's disease pipeline, including the initiation of a first-in-human clinical trial for their LRRK2 inhibitor, BT-267.
Brenig Therapeutics
Brenig Therapeutics is a small molecule drug discovery company focused on developing breakthrough treatments for neurodegenerative diseases. Founded in 2021, the company utilizes advanced hybrid AI/ML platforms, biomarker-driven precision development, and strategic partnerships to accelerate the translation of research into therapies. They aim to deliver best-in-class drug candidates from initial design to clinic within three years, supported by Expert Systems, Inc. Brenig has secured $65 million in Series A financing and is advancing its pre-clinical Parkinson's disease pipeline, including the initiation of a first-in-human clinical trial for their LRRK2 inhibitor, BT-267.